Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

This pilot study was conducted to explore the comparative short-term effects of these interventions individually, and in combination, on weight, body composition and metabolic outcomes.

Diet diaries were utilised to assess compliance.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Measurement of weight and glycated haemoglobin (HbA1c), dual energy X-ray absorptiometry, and intravenous glucose tolerance tests (IVGTT) were performed at baseline and post-intervention.

How the Study Was Run

In design terms this was a randomized and pilot study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Semaglutide study would be practical.

A time span of 12 weeks appears in the methods.

Thirty individuals with T2D (age 18-75 years, BMI 27-50 kg m-2) were randomly assigned to receive Semaglutide (SEM), 800 kilocalorie/day VLCD (VLCD), or both in combination (COMB) for 12 weeks.

Insulin first phase response during IVGTT provided a marker of pancreatic beta-cell function, and insulin sensitivity was estimated using HOMA-IR.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Caloric Restriction, Pilot Projects, Weight Loss, Glycated Hemoglobin and Hypoglycemic Agents.

Author keywords: Beta cell function, Body composition, Obesity, Semaglutide, Type 2 diabetes and Very-low calorie diet.

What This Means in Plain Language

The paper is a randomized and pilot study of Semaglutide over 12 weeks.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Semaglutide compound page, all human trials.